Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)
Status:
Terminated
Trial end date:
2019-06-10
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and effectiveness of different doses of OPK-88004
compared to placebo on serum PSA compared to placebo in men with benign prostatic hyperplasia
(BPH).
Phase:
Phase 2
Details
Lead Sponsor:
OPKO Health, Inc. Transition Therapeutics Ireland Limited